

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis ID6337


Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company	General
AstraZeneca (eplontersen)	All Wales Inherited Metabolic Disease Service
 Patient/carer groups Addenbrookes Liver Transplant Association Arrythmia Alliance Atrial Fibrillation Association British Liver Trust Cardiowyopathy UK Cardiovascular Care Partnership Gene People Genetic Alliance UK HEART UK Liver4Life Myeloma UK Somerville Foundation Specialised Healthcare Alliance UK ATTR Amyloidosis Patients Association Healthcare professional groups Association of British Neurologists Association of Renal Technologists British Association for the Study of the Liver 	 All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Association of Renal Industries Board of Community Health Councils in Wales British National Formulary Care Quality Commission Cell and Gene Therapy Catapult Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Pharmacy Association National Services Division NHS Confederation Scottish Medicines Consortium Scottish Society of Gastroenterology Wales Neurological Alliance Welsh Health Specialised Services Committee
 Liver British Association of Endocrine and Thyroid Surgeons 	 <u>Possible comparator companies</u> Alnylam (patisiran, vutrisiran) Akcea Therapeutics (inotersen)
 British Association of Urological Nurses 	Relevant research groups Brain Research UK

Provisional stakeholder list for the evaluation of eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis ID6337.

Issue date: November 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.




Consultees	Commentators (no right to submit or appeal)
 British Association of Urological Surgeons British Cardiovascular Society British Geriatrics Society British Neuropathological Society British Neuropathological Society British Society for Gene and Cell Therapy British Society of Gastroenterology British Society of Gastroenterology British Society of Paediatric Gastroenterology, Hepatology and Nutrition Institute of Neurology National Heart and Lung Institute National Metabolic Biochemistry Network National Neuroscience Advisory Group Neuromodulation Society of UK and Ireland Primary Care and Community Neurology Society Primary Care Society for Gastroenterology Royal College of General Practitioners Royal College of Physicians Royal Society of Medicine Society for Endocrinology UK Clinical Pharmacy Association Vascular Society of Great Britain and Ireland 	 Circulation Foundation Cochrane UK Cochrane Hepato-Biliary Group Cochrane Metabolic & Endocrine Disorders Group Foundation for Liver Research Genomics England MRC Clinical Trials Unit National Centre for Cardiovascular Preventions and Outcomes National Hospital for Neurology and Neurosurgery National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency
 National Amyloidosis Centre, UCL Department of Health and Social Care NHS England 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected

Provisional stakeholder list for the evaluation of eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis ID6337.

Issue date: November 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.



characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.